Clinipace, a clinical research software firm that recently closed on $2.6 million in new venture funding, is using some of those funds to expand its management team.

Signing on are David Levin as vice president of marketing and Hampton Corley, who will build Clinipace’s sales force.

Levin has worked in the past at etrials and MercuryMD, two other Triangle-based life science firms.

Corley led sales efforts at PSIMedica, a subsidiary of BioReference Laboratories.

"As we continue to grow in this often varied and complex industry, it is critical that the markets we serve — biopharmaceutical, medical device and academic medical research — are crystal clear about how our solutions can improve their post-approval trials, registries, and investigator-initiated research management,” said Clinipace Chief Executive Officer Jeff Williams. “Concurrently, we want to ensure that each customer continues to have a positive experience in all of their interactions with us, and David brings us a 15-year record of successfully positioning companies and their products within the healthcare industry, and delivering positive client satisfaction outcomes.”

We are entering an exciting time for Clinipace and David will spearhead efforts to bring our message, that our software as a service (SaaS) solution can serve the many demands of clinical trials, to more life sciences customers. He will be a key member of our product innovation team and senior management committee.”

Corley will report to Chief Operating Officer Chris Porter.

“Hampton has been an extraordinarily successful sales executive and manager his entire career and is passionate about selling the right product to the right customers to ensure their success.” Porter said. “With over thirteen years of experience in selling software, business service, and analytics solutions, Hampton is a world-class salesperson who has worked for some of the best known sales organizations.”

Clinipace closed on its new financing in January. Hatteras Venture Partners, which is based in Durham, led the round and is a new investor. Also participating were existing investors Brook Private Equity Advisors and Emergent Growth Fund.

Founded in 2004, Clinipace said it will use the funding to expand its sales and marketing efforts. Its primary product is designed to assist clinical trials through workflow analysis, collection and management.